Asthma drug levels tested in teens: will it work the same as in adults?
NCT ID NCT06900816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how much of the asthma drug CHF 6001 gets into the blood of teenagers compared to adults after a single inhaled dose. Fifty people with asthma took part, including teens aged 12 to 17 and adults up to 75 years old. The goal was to see if the drug behaves similarly in both groups, which could help guide future dosing for younger patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CHF 6001 (an inhaled drug for asthma)
- What this could lead to
- If successful, this could help determine the right dose of CHF 6001 for teenagers with asthma, potentially improving treatment.
- What could go wrong
- This is a small, early-phase study focused on drug levels, not on whether the drug works. It may not lead to a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Centre Comac Medical Ltd.
Sofia, Krasno Selo District, 1612, Bulgaria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?